Autopsy report · NCT00240162

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

“investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 3 months before it stopped.
• 21 participants enrolled.
• Results were posted on the registry 5 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

PTK787/ZK 222584

Participants

21

Sites

1

Countries

United States

Trials that died the same way

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
  “Long-term animal toxicology findings (see detailed description).” (58% match in meaning)
• tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
  “Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.” (57% match in meaning)
• Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
  “drug-associated adverse reactions” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.